Click for best price
Kidney Cancer Drugs Market Size, Share 2023
| Market size in 2022 |
US$ 4085 million
|
Forecast Market size by 2029 |
US$ 5417.4 million
|
| Growth Rate |
CAGR of 4.1% |
Number of Pages |
120 Pages |
Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.
This report aims to provide a comprehensive presentation of the global market for Kidney Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer Drugs. This report contains market size and forecasts of Kidney Cancer Drugs in global, including the following market information:
Global Kidney Cancer Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Kidney Cancer Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Kidney Cancer Drugs companies in 2022 (%)
The global Kidney Cancer Drugs market was valued at US$ 4085 million in 2022 and is projected to reach US$ 5417.4 million by 2029, at a CAGR of 4.1% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.
We surveyed the Kidney Cancer Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Kidney Cancer Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Kidney Cancer Drugs Market Segment Percentages, by Type, 2022 (%)
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)
Global Kidney Cancer Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Kidney Cancer Drugs Market Segment Percentages, by Application, 2022 (%)
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)
Global Kidney Cancer Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Kidney Cancer Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Kidney Cancer Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Kidney Cancer Drugs revenues share in global market, 2022 (%)
Key companies Kidney Cancer Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Kidney Cancer Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
Roche
GlaxoSmithKline
Novartis
Pfizer
Abbott Laboratories
Active Biotech
Amgen
Argos Therapeutics
ArQule
AVEO Pharmaceuticals
Bionomics
Bristol-Myers Squibb
Cerulean Pharma
Exelixis
Genentech
immatics biotechnologies
Immunicum
Ono Pharmaceutical
Onyx Therapeutics
Oxford BioMedica
Prometheus Laboratories
Seattle Genetics
Taiwan Liposome
Tracon Pharmaceuticals
Wilex
Outline of Major Chapters:
Chapter 1: Introduces the definition of Kidney Cancer Drugs, market overview.
Chapter 2: Global Kidney Cancer Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Kidney Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Kidney Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Kidney Cancer Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Kidney Cancer Drugs Market, Global Outlook and Forecast 2023-2029 |
| Market size in 2022 |
US$ 4085 million
|
| Forecast Market size by 2029 |
US$ 5417.4 million
|
| Growth Rate |
CAGR of 4.1% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
120 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Kidney Cancer Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Kidney Cancer Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Kidney Cancer Drugs Overall Market Size
2.1 Global Kidney Cancer Drugs Market Size: 2022 VS 2029
2.2 Global Kidney Cancer Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Kidney Cancer Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Kidney Cancer Drugs Players in Global Market
3.2 Top Global Kidney Cancer Drugs Companies Ranked by Revenue
3.3 Global Kidney Cancer Drugs Revenue by Companies
3.4 Global Kidney Cancer Drugs Sales by Companies
3.5 Global Kidney Cancer Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Kidney Cancer Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Kidney Cancer Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Kidney Cancer Drugs Players in Global Market
3.8.1 List of Global Tier 1 Kidney Cancer Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Kidney Cancer Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Kidney Cancer Drugs Market Size Markets, 2022 & 2029
4.1.2 Angiogenesis Inhibitors
4.1.3 mTOR Inhibitors
4.1.4 Monoclonal Antibodies
4.1.5 Cytokine Immunotherapy (IL-2)
4.2 By Type - Global Kidney Cancer Drugs Revenue & Forecasts
4.2.1 By Type - Global Kidney Cancer Drugs Revenue, 2018-2023
4.2.2 By Type - Global Kidney Cancer Drugs Revenue, 2024-2029
4.2.3 By Type - Global Kidney Cancer Drugs Revenue Market Share, 2018-2029
4.3 By Type - Global Kidney Cancer Drugs Sales & Forecasts
4.3.1 By Type - Global Kidney Cancer Drugs Sales, 2018-2023
4.3.2 By Type - Global Kidney Cancer Drugs Sales, 2024-2029
4.3.3 By Type - Global Kidney Cancer Drugs Sales Market Share, 2018-2029
4.4 By Type - Global Kidney Cancer Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Kidney Cancer Drugs Market Size, 2022 & 2029
5.1.2 Renal Cell Carcinoma (RCC)
5.1.3 Transitional Cell Carcinoma (TCC)
5.2 By Application - Global Kidney Cancer Drugs Revenue & Forecasts
5.2.1 By Application - Global Kidney Cancer Drugs Revenue, 2018-2023
5.2.2 By Application - Global Kidney Cancer Drugs Revenue, 2024-2029
5.2.3 By Application - Global Kidney Cancer Drugs Revenue Market Share, 2018-2029
5.3 By Application - Global Kidney Cancer Drugs Sales & Forecasts
5.3.1 By Application - Global Kidney Cancer Drugs Sales, 2018-2023
5.3.2 By Application - Global Kidney Cancer Drugs Sales, 2024-2029
5.3.3 By Application - Global Kidney Cancer Drugs Sales Market Share, 2018-2029
5.4 By Application - Global Kidney Cancer Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Kidney Cancer Drugs Market Size, 2022 & 2029
6.2 By Region - Global Kidney Cancer Drugs Revenue & Forecasts
6.2.1 By Region - Global Kidney Cancer Drugs Revenue, 2018-2023
6.2.2 By Region - Global Kidney Cancer Drugs Revenue, 2024-2029
6.2.3 By Region - Global Kidney Cancer Drugs Revenue Market Share, 2018-2029
6.3 By Region - Global Kidney Cancer Drugs Sales & Forecasts
6.3.1 By Region - Global Kidney Cancer Drugs Sales, 2018-2023
6.3.2 By Region - Global Kidney Cancer Drugs Sales, 2024-2029
6.3.3 By Region - Global Kidney Cancer Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Kidney Cancer Drugs Revenue, 2018-2029
6.4.2 By Country - North America Kidney Cancer Drugs Sales, 2018-2029
6.4.3 US Kidney Cancer Drugs Market Size, 2018-2029
6.4.4 Canada Kidney Cancer Drugs Market Size, 2018-2029
6.4.5 Mexico Kidney Cancer Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Kidney Cancer Drugs Revenue, 2018-2029
6.5.2 By Country - Europe Kidney Cancer Drugs Sales, 2018-2029
6.5.3 Germany Kidney Cancer Drugs Market Size, 2018-2029
6.5.4 France Kidney Cancer Drugs Market Size, 2018-2029
6.5.5 U.K. Kidney Cancer Drugs Market Size, 2018-2029
6.5.6 Italy Kidney Cancer Drugs Market Size, 2018-2029
6.5.7 Russia Kidney Cancer Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Kidney Cancer Drugs Market Size, 2018-2029
6.5.9 Benelux Kidney Cancer Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Kidney Cancer Drugs Revenue, 2018-2029
6.6.2 By Region - Asia Kidney Cancer Drugs Sales, 2018-2029
6.6.3 China Kidney Cancer Drugs Market Size, 2018-2029
6.6.4 Japan Kidney Cancer Drugs Market Size, 2018-2029
6.6.5 South Korea Kidney Cancer Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Kidney Cancer Drugs Market Size, 2018-2029
6.6.7 India Kidney Cancer Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Kidney Cancer Drugs Revenue, 2018-2029
6.7.2 By Country - South America Kidney Cancer Drugs Sales, 2018-2029
6.7.3 Brazil Kidney Cancer Drugs Market Size, 2018-2029
6.7.4 Argentina Kidney Cancer Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Kidney Cancer Drugs Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Kidney Cancer Drugs Sales, 2018-2029
6.8.3 Turkey Kidney Cancer Drugs Market Size, 2018-2029
6.8.4 Israel Kidney Cancer Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Kidney Cancer Drugs Market Size, 2018-2029
6.8.6 UAE Kidney Cancer Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Bayer
7.1.1 Bayer Company Summary
7.1.2 Bayer Business Overview
7.1.3 Bayer Kidney Cancer Drugs Major Product Offerings
7.1.4 Bayer Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Bayer Key News & Latest Developments
7.2 Roche
7.2.1 Roche Company Summary
7.2.2 Roche Business Overview
7.2.3 Roche Kidney Cancer Drugs Major Product Offerings
7.2.4 Roche Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Roche Key News & Latest Developments
7.3 GlaxoSmithKline
7.3.1 GlaxoSmithKline Company Summary
7.3.2 GlaxoSmithKline Business Overview
7.3.3 GlaxoSmithKline Kidney Cancer Drugs Major Product Offerings
7.3.4 GlaxoSmithKline Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.3.5 GlaxoSmithKline Key News & Latest Developments
7.4 Novartis
7.4.1 Novartis Company Summary
7.4.2 Novartis Business Overview
7.4.3 Novartis Kidney Cancer Drugs Major Product Offerings
7.4.4 Novartis Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Novartis Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Kidney Cancer Drugs Major Product Offerings
7.5.4 Pfizer Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 Abbott Laboratories
7.6.1 Abbott Laboratories Company Summary
7.6.2 Abbott Laboratories Business Overview
7.6.3 Abbott Laboratories Kidney Cancer Drugs Major Product Offerings
7.6.4 Abbott Laboratories Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Abbott Laboratories Key News & Latest Developments
7.7 Active Biotech
7.7.1 Active Biotech Company Summary
7.7.2 Active Biotech Business Overview
7.7.3 Active Biotech Kidney Cancer Drugs Major Product Offerings
7.7.4 Active Biotech Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Active Biotech Key News & Latest Developments
7.8 Amgen
7.8.1 Amgen Company Summary
7.8.2 Amgen Business Overview
7.8.3 Amgen Kidney Cancer Drugs Major Product Offerings
7.8.4 Amgen Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Amgen Key News & Latest Developments
7.9 Argos Therapeutics
7.9.1 Argos Therapeutics Company Summary
7.9.2 Argos Therapeutics Business Overview
7.9.3 Argos Therapeutics Kidney Cancer Drugs Major Product Offerings
7.9.4 Argos Therapeutics Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Argos Therapeutics Key News & Latest Developments
7.10 ArQule
7.10.1 ArQule Company Summary
7.10.2 ArQule Business Overview
7.10.3 ArQule Kidney Cancer Drugs Major Product Offerings
7.10.4 ArQule Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.10.5 ArQule Key News & Latest Developments
7.11 AVEO Pharmaceuticals
7.11.1 AVEO Pharmaceuticals Company Summary
7.11.2 AVEO Pharmaceuticals Kidney Cancer Drugs Business Overview
7.11.3 AVEO Pharmaceuticals Kidney Cancer Drugs Major Product Offerings
7.11.4 AVEO Pharmaceuticals Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.11.5 AVEO Pharmaceuticals Key News & Latest Developments
7.12 Bionomics
7.12.1 Bionomics Company Summary
7.12.2 Bionomics Kidney Cancer Drugs Business Overview
7.12.3 Bionomics Kidney Cancer Drugs Major Product Offerings
7.12.4 Bionomics Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.12.5 Bionomics Key News & Latest Developments
7.13 Bristol-Myers Squibb
7.13.1 Bristol-Myers Squibb Company Summary
7.13.2 Bristol-Myers Squibb Kidney Cancer Drugs Business Overview
7.13.3 Bristol-Myers Squibb Kidney Cancer Drugs Major Product Offerings
7.13.4 Bristol-Myers Squibb Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.13.5 Bristol-Myers Squibb Key News & Latest Developments
7.14 Cerulean Pharma
7.14.1 Cerulean Pharma Company Summary
7.14.2 Cerulean Pharma Business Overview
7.14.3 Cerulean Pharma Kidney Cancer Drugs Major Product Offerings
7.14.4 Cerulean Pharma Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.14.5 Cerulean Pharma Key News & Latest Developments
7.15 Exelixis
7.15.1 Exelixis Company Summary
7.15.2 Exelixis Business Overview
7.15.3 Exelixis Kidney Cancer Drugs Major Product Offerings
7.15.4 Exelixis Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.15.5 Exelixis Key News & Latest Developments
7.16 Genentech
7.16.1 Genentech Company Summary
7.16.2 Genentech Business Overview
7.16.3 Genentech Kidney Cancer Drugs Major Product Offerings
7.16.4 Genentech Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.16.5 Genentech Key News & Latest Developments
7.17 immatics biotechnologies
7.17.1 immatics biotechnologies Company Summary
7.17.2 immatics biotechnologies Business Overview
7.17.3 immatics biotechnologies Kidney Cancer Drugs Major Product Offerings
7.17.4 immatics biotechnologies Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.17.5 immatics biotechnologies Key News & Latest Developments
7.18 Immunicum
7.18.1 Immunicum Company Summary
7.18.2 Immunicum Business Overview
7.18.3 Immunicum Kidney Cancer Drugs Major Product Offerings
7.18.4 Immunicum Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.18.5 Immunicum Key News & Latest Developments
7.19 Ono Pharmaceutical
7.19.1 Ono Pharmaceutical Company Summary
7.19.2 Ono Pharmaceutical Business Overview
7.19.3 Ono Pharmaceutical Kidney Cancer Drugs Major Product Offerings
7.19.4 Ono Pharmaceutical Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.19.5 Ono Pharmaceutical Key News & Latest Developments
7.20 Onyx Therapeutics
7.20.1 Onyx Therapeutics Company Summary
7.20.2 Onyx Therapeutics Business Overview
7.20.3 Onyx Therapeutics Kidney Cancer Drugs Major Product Offerings
7.20.4 Onyx Therapeutics Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.20.5 Onyx Therapeutics Key News & Latest Developments
7.21 Oxford BioMedica
7.21.1 Oxford BioMedica Company Summary
7.21.2 Oxford BioMedica Business Overview
7.21.3 Oxford BioMedica Kidney Cancer Drugs Major Product Offerings
7.21.4 Oxford BioMedica Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.21.5 Oxford BioMedica Key News & Latest Developments
7.22 Prometheus Laboratories
7.22.1 Prometheus Laboratories Company Summary
7.22.2 Prometheus Laboratories Business Overview
7.22.3 Prometheus Laboratories Kidney Cancer Drugs Major Product Offerings
7.22.4 Prometheus Laboratories Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.22.5 Prometheus Laboratories Key News & Latest Developments
7.23 Seattle Genetics
7.23.1 Seattle Genetics Company Summary
7.23.2 Seattle Genetics Business Overview
7.23.3 Seattle Genetics Kidney Cancer Drugs Major Product Offerings
7.23.4 Seattle Genetics Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.23.5 Seattle Genetics Key News & Latest Developments
7.24 Taiwan Liposome
7.24.1 Taiwan Liposome Company Summary
7.24.2 Taiwan Liposome Business Overview
7.24.3 Taiwan Liposome Kidney Cancer Drugs Major Product Offerings
7.24.4 Taiwan Liposome Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.24.5 Taiwan Liposome Key News & Latest Developments
7.25 Tracon Pharmaceuticals
7.25.1 Tracon Pharmaceuticals Company Summary
7.25.2 Tracon Pharmaceuticals Business Overview
7.25.3 Tracon Pharmaceuticals Kidney Cancer Drugs Major Product Offerings
7.25.4 Tracon Pharmaceuticals Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.25.5 Tracon Pharmaceuticals Key News & Latest Developments
7.26 Wilex
7.26.1 Wilex Company Summary
7.26.2 Wilex Business Overview
7.26.3 Wilex Kidney Cancer Drugs Major Product Offerings
7.26.4 Wilex Kidney Cancer Drugs Sales and Revenue in Global (2018-2023)
7.26.5 Wilex Key News & Latest Developments
8 Global Kidney Cancer Drugs Production Capacity, Analysis
8.1 Global Kidney Cancer Drugs Production Capacity, 2018-2029
8.2 Kidney Cancer Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Kidney Cancer Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Kidney Cancer Drugs Supply Chain Analysis
10.1 Kidney Cancer Drugs Industry Value Chain
10.2 Kidney Cancer Drugs Upstream Market
10.3 Kidney Cancer Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Kidney Cancer Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Kidney Cancer Drugs in Global Market
Table 2. Top Kidney Cancer Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Kidney Cancer Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Kidney Cancer Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Kidney Cancer Drugs Sales by Companies, (K Units), 2018-2023
Table 6. Global Kidney Cancer Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Kidney Cancer Drugs Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Kidney Cancer Drugs Product Type
Table 9. List of Global Tier 1 Kidney Cancer Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Kidney Cancer Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Kidney Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Kidney Cancer Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Kidney Cancer Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Kidney Cancer Drugs Sales (K Units), 2018-2023
Table 15. By Type - Global Kidney Cancer Drugs Sales (K Units), 2024-2029
Table 16. By Application ? Global Kidney Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Kidney Cancer Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Kidney Cancer Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Kidney Cancer Drugs Sales (K Units), 2018-2023
Table 20. By Application - Global Kidney Cancer Drugs Sales (K Units), 2024-2029
Table 21. By Region ? Global Kidney Cancer Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Kidney Cancer Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Kidney Cancer Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Kidney Cancer Drugs Sales (K Units), 2018-2023
Table 25. By Region - Global Kidney Cancer Drugs Sales (K Units), 2024-2029
Table 26. By Country - North America Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Kidney Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Kidney Cancer Drugs Sales, (K Units), 2018-2023
Table 29. By Country - North America Kidney Cancer Drugs Sales, (K Units), 2024-2029
Table 30. By Country - Europe Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Kidney Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Kidney Cancer Drugs Sales, (K Units), 2018-2023
Table 33. By Country - Europe Kidney Cancer Drugs Sales, (K Units), 2024-2029
Table 34. By Region - Asia Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Kidney Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Kidney Cancer Drugs Sales, (K Units), 2018-2023
Table 37. By Region - Asia Kidney Cancer Drugs Sales, (K Units), 2024-2029
Table 38. By Country - South America Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Kidney Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Kidney Cancer Drugs Sales, (K Units), 2018-2023
Table 41. By Country - South America Kidney Cancer Drugs Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Kidney Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Kidney Cancer Drugs Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Kidney Cancer Drugs Sales, (K Units), 2024-2029
Table 46. Bayer Company Summary
Table 47. Bayer Kidney Cancer Drugs Product Offerings
Table 48. Bayer Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Bayer Key News & Latest Developments
Table 50. Roche Company Summary
Table 51. Roche Kidney Cancer Drugs Product Offerings
Table 52. Roche Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Roche Key News & Latest Developments
Table 54. GlaxoSmithKline Company Summary
Table 55. GlaxoSmithKline Kidney Cancer Drugs Product Offerings
Table 56. GlaxoSmithKline Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. GlaxoSmithKline Key News & Latest Developments
Table 58. Novartis Company Summary
Table 59. Novartis Kidney Cancer Drugs Product Offerings
Table 60. Novartis Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Novartis Key News & Latest Developments
Table 62. Pfizer Company Summary
Table 63. Pfizer Kidney Cancer Drugs Product Offerings
Table 64. Pfizer Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Pfizer Key News & Latest Developments
Table 66. Abbott Laboratories Company Summary
Table 67. Abbott Laboratories Kidney Cancer Drugs Product Offerings
Table 68. Abbott Laboratories Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. Abbott Laboratories Key News & Latest Developments
Table 70. Active Biotech Company Summary
Table 71. Active Biotech Kidney Cancer Drugs Product Offerings
Table 72. Active Biotech Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Active Biotech Key News & Latest Developments
Table 74. Amgen Company Summary
Table 75. Amgen Kidney Cancer Drugs Product Offerings
Table 76. Amgen Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Amgen Key News & Latest Developments
Table 78. Argos Therapeutics Company Summary
Table 79. Argos Therapeutics Kidney Cancer Drugs Product Offerings
Table 80. Argos Therapeutics Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. Argos Therapeutics Key News & Latest Developments
Table 82. ArQule Company Summary
Table 83. ArQule Kidney Cancer Drugs Product Offerings
Table 84. ArQule Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. ArQule Key News & Latest Developments
Table 86. AVEO Pharmaceuticals Company Summary
Table 87. AVEO Pharmaceuticals Kidney Cancer Drugs Product Offerings
Table 88. AVEO Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 89. AVEO Pharmaceuticals Key News & Latest Developments
Table 90. Bionomics Company Summary
Table 91. Bionomics Kidney Cancer Drugs Product Offerings
Table 92. Bionomics Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 93. Bionomics Key News & Latest Developments
Table 94. Bristol-Myers Squibb Company Summary
Table 95. Bristol-Myers Squibb Kidney Cancer Drugs Product Offerings
Table 96. Bristol-Myers Squibb Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 97. Bristol-Myers Squibb Key News & Latest Developments
Table 98. Cerulean Pharma Company Summary
Table 99. Cerulean Pharma Kidney Cancer Drugs Product Offerings
Table 100. Cerulean Pharma Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 101. Cerulean Pharma Key News & Latest Developments
Table 102. Exelixis Company Summary
Table 103. Exelixis Kidney Cancer Drugs Product Offerings
Table 104. Exelixis Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 105. Exelixis Key News & Latest Developments
Table 106. Genentech Company Summary
Table 107. Genentech Kidney Cancer Drugs Product Offerings
Table 108. Genentech Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 109. Genentech Key News & Latest Developments
Table 110. immatics biotechnologies Company Summary
Table 111. immatics biotechnologies Kidney Cancer Drugs Product Offerings
Table 112. immatics biotechnologies Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 113. immatics biotechnologies Key News & Latest Developments
Table 114. Immunicum Company Summary
Table 115. Immunicum Kidney Cancer Drugs Product Offerings
Table 116. Immunicum Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 117. Immunicum Key News & Latest Developments
Table 118. Ono Pharmaceutical Company Summary
Table 119. Ono Pharmaceutical Kidney Cancer Drugs Product Offerings
Table 120. Ono Pharmaceutical Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 121. Ono Pharmaceutical Key News & Latest Developments
Table 122. Onyx Therapeutics Company Summary
Table 123. Onyx Therapeutics Kidney Cancer Drugs Product Offerings
Table 124. Onyx Therapeutics Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 125. Onyx Therapeutics Key News & Latest Developments
Table 126. Oxford BioMedica Company Summary
Table 127. Oxford BioMedica Kidney Cancer Drugs Product Offerings
Table 128. Oxford BioMedica Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 129. Oxford BioMedica Key News & Latest Developments
Table 130. Prometheus Laboratories Company Summary
Table 131. Prometheus Laboratories Kidney Cancer Drugs Product Offerings
Table 132. Prometheus Laboratories Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 133. Prometheus Laboratories Key News & Latest Developments
Table 134. Seattle Genetics Company Summary
Table 135. Seattle Genetics Kidney Cancer Drugs Product Offerings
Table 136. Seattle Genetics Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 137. Seattle Genetics Key News & Latest Developments
Table 138. Taiwan Liposome Company Summary
Table 139. Taiwan Liposome Kidney Cancer Drugs Product Offerings
Table 140. Taiwan Liposome Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 141. Taiwan Liposome Key News & Latest Developments
Table 142. Tracon Pharmaceuticals Company Summary
Table 143. Tracon Pharmaceuticals Kidney Cancer Drugs Product Offerings
Table 144. Tracon Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 145. Tracon Pharmaceuticals Key News & Latest Developments
Table 146. Wilex Company Summary
Table 147. Wilex Kidney Cancer Drugs Product Offerings
Table 148. Wilex Kidney Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 149. Wilex Key News & Latest Developments
Table 150. Kidney Cancer Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 151. Global Kidney Cancer Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 152. Global Kidney Cancer Drugs Production by Region, 2018-2023 (K Units)
Table 153. Global Kidney Cancer Drugs Production by Region, 2024-2029 (K Units)
Table 154. Kidney Cancer Drugs Market Opportunities & Trends in Global Market
Table 155. Kidney Cancer Drugs Market Drivers in Global Market
Table 156. Kidney Cancer Drugs Market Restraints in Global Market
Table 157. Kidney Cancer Drugs Raw Materials
Table 158. Kidney Cancer Drugs Raw Materials Suppliers in Global Market
Table 159. Typical Kidney Cancer Drugs Downstream
Table 160. Kidney Cancer Drugs Downstream Clients in Global Market
Table 161. Kidney Cancer Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Kidney Cancer Drugs Segment by Type in 2022
Figure 2. Kidney Cancer Drugs Segment by Application in 2022
Figure 3. Global Kidney Cancer Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Kidney Cancer Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Kidney Cancer Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Kidney Cancer Drugs Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Kidney Cancer Drugs Revenue in 2022
Figure 9. By Type - Global Kidney Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Kidney Cancer Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Kidney Cancer Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Kidney Cancer Drugs Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Kidney Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Kidney Cancer Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Kidney Cancer Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Kidney Cancer Drugs Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Kidney Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Kidney Cancer Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Kidney Cancer Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Kidney Cancer Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Kidney Cancer Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Kidney Cancer Drugs Sales Market Share, 2018-2029
Figure 23. US Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Kidney Cancer Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Kidney Cancer Drugs Sales Market Share, 2018-2029
Figure 28. Germany Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Kidney Cancer Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Kidney Cancer Drugs Sales Market Share, 2018-2029
Figure 37. China Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Kidney Cancer Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Kidney Cancer Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Kidney Cancer Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Kidney Cancer Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Kidney Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Kidney Cancer Drugs Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Kidney Cancer Drugs by Region, 2022 VS 2029
Figure 54. Kidney Cancer Drugs Industry Value Chain
Figure 55. Marketing Channels
